Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AxeCan: Axelopran in Advanced Cancers on Opioids
NCT07354919Phase 2Recruiting
- Sponsor
- HealthPartners Institute
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axelopran in breast cancer, lung cancer, pancreatic cancer (PC), prostate cancer (PCa), sponsored by HealthPartners Institute. Started Apr 2026; status: recruiting.
02
Drugs
axelopran
03
Conditions
breast cancerlung cancerpancreatic cancer (PC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07354919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354919.